CAR-X
Cell Therapy
Cell-Based IO
Collaborations, Mergers & Acquisitions
Finance & Investment
Gene Editing
Gene Therapy

£900 Million Investment to Expand UK Bioscience Hub – in the Largest Clusters of Life Sciences Companies in Europe

Anna Osborne
7 July 2022
SHARE NOW
World-leading life science park Stevenage Bioscience Catalyst, located in Europe’s largest cluster of cell and gene therapy companies in the UK, that includes Cell and Gene Therapy Catapult and GSK’s Global R&D center, shares plans for facility expansion using £900 million of new investment.

The expansion will see the addition of an estimated 1.4 million square feet of laboratory and office facilities, creating up to 5000 new jobs.

“The Stevenage campus is already a leading location for life science companies to develop and commercialize cutting edge therapeutics. It is a unique location that brings together major multinationals, the Cell and Gene Therapy Catapult Manufacturing Centre and Stevenage Bioscience Catalyst’s 40+ biotech companies. This makes it a powerhouse for innovation and we are looking forward to working with Reef Group and other stakeholders to further develop the thriving life sciences campus in Stevenage,” said Dr Sally Ann Forsyth OBE, CEO, Stevenage Bioscience Catalyst.

How are you enjoying this article? Let us know your thoughts, here >>

Investment for the new campus, which will sit alongside the Stevenage Bioscience Catalyst (SBC) center and the Cell and Gene Therapy Catapult and GSK’s Global R&D center, is to be provided by UBS Asset Management and Reef Group, and developed in partnership with SBC, GSK, the UK Government, Hertfordshire Local Enterprise Partnership and Stevenage Borough Council.

UBS Asset Management and Reef Group’s £900m investment adds to the total £2.9b financings secured collectively by the cluster of cell and gene therapy companies located at the Stevenage hub, that has formed a supportive environment of specialist equipment, facilities for development and manufacturing, and mentoring for biotechs.

The new campus is set to be built on 33 acres of land purchased from GSK, as well as additional land gifted by GSK to UBS and Reef. GSK has also announced they will waiver a 2012 loan made to SBC, in support of the project.

Piers Slater, Joint Chief Executive, Reef Group, commented “we are excited to be working with GSK and UBS to deliver a unique and world-leading development that will be an incredible catalyst for innovation in life sciences R&D. Our vision is to bring together the best of academia and industry in a diverse and world-class mix of life sciences spaces, with digital infrastructure, sustainability and connectivity at their core.”

Construction is set to begin in 2023, with some parts of the site estimated to be open by 2025, as SBC continues to accelerate the translation of cutting-edge science to improve human health.

Source: Stevenage Bioscience Catalyst Press Releases

Find out more about and register your place at Phacilitate’s Advanced Therapies Europe 2022 here >>


While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.